Search Results - "Lakatos, P.L"

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis by Stange, E F, Travis, S P L, Vermeire, S, Reinisch, W, Geboes, K, Barakauskiene, A, Feakins, R, Fléjou, J F, Herfarth, H, Hommes, D W, Kupcinskas, L, Lakatos, P L, Mantzaris, G J, Schreiber, S, Villanacci, V, Warren, B F

Get full text

ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients by Lakatos, P.L, Szamosi, T, Szilvasi, A, Molnar, E, Lakatos, L, Kovacs, A, Molnar, T, Altorjay, I, Papp, M, Tulassay, Z, Miheller, P, Papp, J, Tordai, A, Andrikovics, H

“…Abstract Background North American and European genome-wide association scans have identified ATG16L1 and IL23R as novel inflammatory bowel disease (IBD)…”
Get full text

NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease by Molnar, T, Hofner, P, Nagy, F, Lakatos, P.L, Fischer, S, Lakatos, L, Kovacs, A, Altorjay, I, Papp, M, Palatka, K, Demeter, P, Tulassay, Z, Nyari, T, Miheller, P, Papp, J, Mandi, Y, Lonovics, J

“…Abstract Background NOD1/CARD4, a member of the pattern-recognition receptor family, is a perfect candidate as a susceptibility gene for Crohn's disease. Since…”
Get full text

183 MANNOSE-BINDING LECTIN DEFICIENCY CONFERS RISK FOR INFECTIONS IN A LARGE HUNGARIAN COHORT OF PATIENTS WITH LIVER CIRRHOSIS by Papp, M, Vitalis, Z, Tornai, I, Palatka, K, Kacska, S, Farkas, G, Udvardy, M, Harsfalvi, J, Dinya, T, Orosz, P, Lombay, B, Par, A, Par, G, Csak, T, Osztovics, J, Szalay, F, Csepregi, A, Lakatos, P.L, Altrojay, I

Get full text

PCR225 The Added Value of the Cognition, Dining, Gastrointestinal Problems, Sleep, and Tiredness Bolt-Ons for the EQ-5D-5L in Patients With Coeliac Disease by Angyal, M., Janssen, M.F., Lakatos, P.L., Brodszky, V., Rencz, F.

Get full text

PGI50 - HAPPY TOMORROW BUT GLOOMING ELDERLY? SELF-ESTIMATION OF FUTURE HEALTH IN CROHN’S DISEASE by Péntek, M., Gulácsi, L., Herszényi, L., Palatka, K., Lakatos, P.L., Banai, J., Brodszky, V., Rencz, F.

Get full text

Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort by Al Khoury, A., Xiao, Y., Golovics, P.A., Kohen, R., Afif, W., Wild, G., Friedman, G., Galiatsatos, P., Hilzenrat, N., Szilagyi, A., Wyse, J., Cohen, A., Bitton, A., Bessissow, T., Lakatos, P.L.

“…Data suggests that tight objective monitoring may improve clinical outcomes in IBD. To assess the adherence to serial tight objective monitoring(clinical and…”
Get full text

P152 Reconsidering the prognostic value of traditional serologic antibodies in Crohn's disease – immunoglobulin classes to take the centre stage by Sipeki, N., Norman, G.L., Shums, Z., Veres, G., Lakatos, P.L., Antal-Szalmas, P., Papp, M.

Get full text

P309 Impact of rapid access MR on clinical decision making and patient management in Crohn's disease in a tertiary referral center by Lovasz, B.D., Gonczi, L., Kurti, Z., Vegh, Z., Golovics, P.A., Rudas, G., Gecse, K.B., Lakatos, P.L.

Get full text

P145 Measuring access and quality of care indicators in inflammatory bowel disease in a tertiary referral center by Golovics, P.A., Gonczi, L., Kurti, Z., Lovasz, B.D., Gecse, K.B., Vegh, Z., Lakatos, P.L.

Get full text

Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort by Vegh, Z., Burisch, J., Pedersen, N., Kaimakliotis, I., Duricova, D., Bortlik, M., Avnstrøm, S., Vinding, K. Kofod, Olsen, J., Nielsen, K.R., Katsanos, K.H., Tsianos, E.V., Lakatos, L., Schwartz, D., Odes, S., Lupinacci, G., De Padova, A., Jonaitis, L., Kupcinskas, L., Turcan, S., Tighineanu, O., Mihu, I., Barros, L.F., Magro, F., Lazar, D., Goldis, A., Fernandez, A., Hernandez, V., Niewiadomski, O., Bell, S., Langholz, E., Munkholm, P., Lakatos, P.L.

“…The aim of the present study was to validate the IBD (inflammatory bowel diseases) incidence reported in the 2010 ECCO-EpiCom (European Crohn's and Colitis…”
Get full text

P623 Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database by Gonczi, L., Vegh, Z., Kurti, Z., Lovasz, B.D., Golovics, P.A., Fadgyas-Freyler, P., Gimesi-Orszagh, J., Gecse, K.B., Lakatos, P.L.

Get full text

P675 Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis – 54 week data by Molnár, T., Farkas, K., Rutka, M., Ferenci, T., Nagy, F., Bálint, A., Bor, R., Milassin, A., Fábián, A., Végh, Z., Kürti, Z., Lakatos, P.L., Szepes, Z.

Get full text

P411 Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases by Kurti, Z., Rutka, M., Vegh, Z., Gonczi, L., Farkas, K., Lovasz, B.D., Gecse, K.B., Golovics, P.A., Szalay, B., Molnar, T., Lakatos, P.L.

Get full text

P649 Relationship between clinical characteristics and vitamin D receptor polymorphisms in Crohn's disease by Terjek, O., Csontos, A.A., Lorinczy, K., Bors, A., Torday, A., Lakatos, P.L., Miheller, P.

Get full text

P734 The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey by Shah, S.C., Khalili, H., Gower-Rousseau, C., Olén, O., Benchimol, E., Lynge, E., Nielsen, K., Ahn, H., Brassard, P., Vutcovici, M., Bitton, A., Bernstein, C., Leddin, D., Tamim, H., Aniwan, S., Chen, C.-Y., Stefánsson, T., Loftus, E.V., Moum, B., Tang, W., Ng, S., Gearry, R., Sincic, B., Bell, S., Lakatos, P.L., Végh, Z., Ott, C., Kaplan, G., Burisch, J., Colombel, J.-F.

Get full text

P695 The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort by Burisch, J., Halfvarson, J., Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J.F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K.R., Giannotta, M., Oksanen, P., Katsanos, K.H., Vegh, Z., Ellul, P., Schwartz, D., Čuković-Čavka, S., D'Incà, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P.L., Munkholm, P.

Get full text

P694 Disease course during the first five years following diagnosis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort by Burisch, J., Halfvarson, J., Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J.F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K.R., Giannotta, M., Oksanen, P., Katsanos, K.H., Vegh, Z., Ellul, P., Schwartz, D., Čuković-Čavka, S., D'Incà, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P.L., Munkholm, P.

Get full text

P727 Change in Crohn's disease behavior in a prospective European population-based inception cohort – the ECCO-EpiCom cohort by Burisch, J., Halfvarson, J., Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J.F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K.R., Giannotta, M., Oksanen, P., Katsanos, K.H., Vegh, Z., Ellul, P., Schwartz, D., Čuković-Čavka, S., D'Incà, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P.L., Munkholm, P.

Get full text

P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort by Lovasz, B.D., Kurti, Z., Rutka, M., Vegh, Z., Gecse, K.B., Farkas, K., Banai, J., Bene, L., Golovics, P.A., Gonczi, L., Gasztonyi, B., Kristof, T., Lakatos, L., Miheller, P., Palatka, K., Patai, A., Papp, M., Salamon, A., Szamosi, T., Szepes, Z., Toth, G.T., Vincze, A., Szalay, B., Molnar, T., Lakatos, P.L.

Get full text